Saundra Pelletier

Ms. Pelletier joined the board of directors in 2020 and is Chief Executive Officer, President and Executive Director of Evofem Biosciences, Inc. (NASDAQ:EVFM). Evofem is a female-forward commercial company revolutionizing women’s healthcare with game-changing products, including Phexxi(r), the first – and highly anticipated – hormone-free, on-demand female contraceptive gel. The company has also advanced its investigational product candidate, EVO100, into a Phase 3 clinical trial for the prevention of urogenital transmission of both chlamydia and gonorrhea in women and expects to report top-line data in mid-2022. Ms. Pelletier brings more than two decades of broad executive leadership experience to TRACON, including an outstanding track record leading multiple successful product launches, expanding commercial capabilities in ex-U.S. markets and advocating for women’s health. Earlier in her career, Saundra served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit focused on women’s healthcare. She later moved to Women First Healthcare, where she served as Vice President of Pharmaceuticals and raised $40 million in capital. She also spent several years as a corporate consultant/executive business coach working with teams at Pfizer, Boehringer Ingelheim Pharmaceuticals, Valeant Pharmaceuticals International, Somaxon, Biovascular Inc. and Two Jinn. She has been responsible for Evofem’s rapid growth and evolution, including the company’s transition to the public market in January 2018 and multiple equity financing rounds that have raised in excess of $425 million. Among her many honors, Ms. Pelletier was named San Diego Business Journal’s 2019 Businesswoman of the Year.